

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	Confirmation Number	3740
	Application Number	10/690,115
	Filing Date	October 21, 2003
	First Named Inventor	Richard Apodaca
	Group Art Unit	1624
	Examiner Name	Brenda L. Coleman
	Attorney Docket Number	PRD2033USNP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Kind Code ² (if known)	Number			
			2004/0110746	A1	Apodaca et al.	06-10-2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	05/0401 44	A1	Glaxo Group Limited	05-06-2005		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BARBIER, A.J. et al.: "Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H ₃ antagonist"; British J. of Pharmacology (2004) 143: 649-661.	
		BERGE, SM. et al.: "Pharmaceutical Salts"; J. of Pharmaceutical Sciences (1977) 66(1): 1-19.	
		CELANIRE, S. et al.: "Histamine H ₃ receptor antagonists reach out for the clinic"; DDT (12/2005) 10(23/24): 1613-1627.	
		CHEN, Z.: "Effect of histamine H ₃ -receptor antagonist clobenpropit on spatial memory of radial maze performance in rats"; Acta Pharmacol Sin (2000) 21(10): 905-910.	
		FOX, G.B. et al.: "Effects of histamine H ₃ receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup"; Behavioural Brain Research 131 (2002): 151-161.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Confirmation Number	3740
Application Number	10/690,115
Filing Date	October 21, 2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda L. Coleman
Attorney Docket Number	PRD2033USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GILLASPY, M.L. et al.: "A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine"; Tetrahedron Letters (1995) 36(41): 7399-7402.	
		HANCOCK, A.A.: "The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H ₃ antagonists/inverse agonists"; Elsevier Biochem. Pharmacology (2006) 71: 1103-1113	
		IRELAND-DENNY, L. et al.: "Species-related pharmacological heterogeneity of histamine H ₃ receptors"; Elsevier European J. of Pharmacology 433 (2001): 141-150.	
		LAMBERTI, C. et al.: "Antidepressant-like effects of endogenous histamine and of two histamine H ₁ receptor agonists in the mouse forced swim test"; British J. of Pharmacology (1998) 123: 1331-1336.	
		LOVE, P. et al.: "Polar Substituent Effects in Gas-Phase Lewis Acid-Base Equilibria. I. Intrinsic Basicity of Amines ¹ "; J. of the Am. Chem. Society (5/1968) 90(10): 2455-2462	
		MIYAZAKI, S. et al.: "Effects of Thioperamide, a Histamine H ₃ -receptor Antagonist, on a Scopolamine-induced Learning Deficit Using an Elevated Plus-maze Test in Mice"; Life Sciences, (1995) 57(23): 2137-2144.	
		MIYAZAKI, S. et al.: "Effects of Thioperamide on the Cholinergic System and the Step-Through Passive Avoidance Test in Mice"; Meth Find Exp Clin Pharmacol (1995) 17(10): 653-658.	
		ORSETTI, M. et al.: "Histamine H ₃ -receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task"; Elsevier Behavioural Brain Research 124 (2001): 235-242.	
		PEREZ-GARCIA, C. et al.: "Effects of histamine H ₃ receptor ligands in experimental models of anxiety and depression"; Psychopharmacology (1999) 142: 215-220.	
		ZARAGOZA, F. et al.: "1-Alkyl-4-acylpiperazines as a New Class of Imidazole-Free Histamine H ₃ Receptor Antagonists"; J. Med. Chem. (2004) 47: 2833-2838.	
		ZARAGOZA, F. et al.: "2-(4-Alkylpiperazin-1-yl)quinolines as a New Class of Imidazole-Free Histamine H ₃ Receptor Antagonists"; J. Med. Chem. (2005) 48: 306-311.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.